Effectiveness of Evusheld in Immunocompromised Patients: Propensity Score-Matched Analysis.

ABSTRACT:

Background

Tixagevimab and Cilgavimab, a combined monoclonal antibody (Evusheld) was granted emergency use authorization for SARS-CoV-2 preexposure prophylaxis in individuals with moderate to severe immunocompromising condition. In this study we used population-based real-world data to evaluate the effectiveness of Evusheld in immunocompromised patients.

Methods

Using the computerized database of the largest healthcare provider in Israel, we identified all adult immunocompromised patients who were eligible to receive Evusheld (the dose used during the study period was 150 mg Tixagevimab and 150 mg Cilgavimab) on 15-February-2022. Patients with a documentation of a prior SARS-CoV-2 infection were excluded. A total of 703 patients who received Evusheld were propensity score-ma

SUBMITTER: Najjar-Debbiny R 

PROVIDER: S-EPMC9623900 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature